Determinants of bone mass in systemic lupus erythematosus: A cross sectional study on premenopausal women

被引:0
作者
Sinigaglia, L
Varenna, M
Binelli, L
Zucchi, F
Ghiringhelli, D
Gallazzi, M
Limonta, M
Zeni, S
Fantini, F
机构
[1] Univ Milan, Ist Ortoped Gaetano Pini, Dept Rheumatol, Div Reumatol, I-20123 Milan, Italy
[2] Univ Milan, Ist Ortoped Gaetano Pini, Dept Radiol, I-20123 Milan, Italy
关键词
systemic lupus erythematosus; bone mineral density; osteoporosis;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective, To evaluate bone mineral density (BMD) in young ambulatory female patients with systemic lupus erythematosus (SLE) and to assess the influence of disease related variables and use of corticosteroids. Methods. Lumbar and femoral BMD were measured by dual x-ray absorptiometry (DXA) in 84 premenopausal patients with SLE (age 30.5 +/- 7.5 years). All patients were receiving corticosteroids at the time of the study. Variables evaluated were: disease duration, clinical pattern, disease activity (SLEDAI), cumulative damage index (SLICC/ACR), current and cumulative prednisone dose, duration of steroid treatment, and use of immunosuppressive agents. Osteoporosis was defined as a t score below 2.5 SD compared to a reference population of healthy women in at least one region of measurement. Results. Vertebral and femoral BMD were significantly lower in patients with SLE than in age matched controls. Osteoporosis was detected in 22.6% of patients. No significant differences in BMD were detected between patients according to clinical pattern or activity index, whereas patients with damage index > 0 (n = 46) had a significantly lower BMD at both the lumbar (p = 0.008) and the femoral (p = 0.05) level. Compared with non-osteoporotic patients with SLE, women with osteoporosis had similar age, lower body mass index, significantly longer disease duration (p < 0.0001), higher cumulative steroid intake (p < 0.006), and higher SLICC/ACR score (p < 0.01). Stepwise logistic regression analysis showed that disease duration is independently associated with osteoporosis (OR 1.2 for each year of disease, 95% CI 1.07-1.33). Since disease duration and duration of steroid treatment were highly correlated, a new stepwise logistic model was run without disease duration, which revealed that prednisone was associated with an increased risk for osteoporosis (OR 1.16 for each year of treatment, 95% CI 1.05-1.29), Conclusion, Osteoporosis is a frequent feature in young patients with SLE. Disease duration is associated with an increased risk for osteoporosis, but the role of glucocorticoid treatment seems to be crucial. Steroid exposure was the only treatment related variable exerting an influence on the development of osteoporosis.
引用
收藏
页码:1280 / 1284
页数:5
相关论文
共 23 条
[1]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[2]   ASSESSMENT OF THE EFFECT OF ORAL CORTICOSTEROIDS ON BONE-MINERAL DENSITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A PRELIMINARY-STUDY WITH DUAL ENERGY X-RAY ABSORPTIOMETRY [J].
DHILLON, VB ;
DAVIES, MC ;
HALL, ML ;
ROUND, JM ;
ELL, PJ ;
JACOBS, HS ;
SNAITH, ML ;
ISENBERG, DA .
ANNALS OF THE RHEUMATIC DISEASES, 1990, 49 (08) :624-626
[3]   LOSS OF BONE-MINERAL DENSITY IN PREMENOPAUSAL WOMEN WITH SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
FORMIGA, F ;
MOGA, I ;
NOLLA, JM ;
PAC, M ;
MITJAVILA, F ;
ROIGESCOFET, D .
ANNALS OF THE RHEUMATIC DISEASES, 1995, 54 (04) :274-276
[4]   Sequential study of bone mineral density in patients with systemic lupus erythematosus [J].
Formiga, F ;
Nolla, JM ;
Moga, I ;
RoigEscofet, D .
ANNALS OF THE RHEUMATIC DISEASES, 1996, 55 (11) :857-857
[5]   The development and initial validation of the systemic lupus international collaborating clinics American College of Rheumatology Damage Index for Systemic Lupus Erythematosus [J].
Gladman, D ;
Ginzler, E ;
Goldsmith, C ;
Fortin, P ;
Liang, M ;
Urowitz, M ;
Bacon, P ;
Bombardieri, S ;
Hanly, J ;
Hay, E ;
Isenberg, D ;
Jones, J ;
Kalunian, K ;
Maddison, P ;
Nived, O ;
Petri, M ;
Richter, M ;
SanchezGuerrero, J ;
Snaith, M ;
Sturfelt, G ;
Symmons, D ;
Zoma, A .
ARTHRITIS AND RHEUMATISM, 1996, 39 (03) :363-369
[6]  
Hansen M, 1998, SCAND J RHEUMATOL, V27, P197
[7]  
Houssiau FA, 1996, BRIT J RHEUMATOL, V35, P244
[8]  
ISRAELI ML, 1991, J IMMUNOL, V147, P117
[9]   LOSS OF TRABECULAR BONE-MINERAL DENSITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
KALLA, AA ;
FATAAR, AB ;
JESSOP, SJ ;
BEWERUNGE, L .
ARTHRITIS AND RHEUMATISM, 1993, 36 (12) :1726-1734
[10]   MORTALITY AND MORBIDITY AFTER HIP-FRACTURES [J].
KEENE, GS ;
PARKER, MJ ;
PRYOR, GA .
BRITISH MEDICAL JOURNAL, 1993, 307 (6914) :1248-1250